1. Home
  2. PROF vs RLMD Comparison

PROF vs RLMD Comparison

Compare PROF & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Profound Medical Corp.

PROF

Profound Medical Corp.

HOLD

Current Price

$7.48

Market Cap

270.7M

Sector

Health Care

ML Signal

HOLD

Logo Relmada Therapeutics Inc.

RLMD

Relmada Therapeutics Inc.

HOLD

Current Price

$4.80

Market Cap

319.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PROF
RLMD
Founded
N/A
2004
Country
Canada
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
270.7M
319.7M
IPO Year
2017
2012

Fundamental Metrics

Financial Performance
Metric
PROF
RLMD
Price
$7.48
$4.80
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
4
Target Price
$12.00
$10.25
AVG Volume (30 Days)
145.3K
587.6K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
19.21
EPS
1.14
N/A
Revenue
$10,680,000.00
$13,070.00
Revenue This Year
$61.09
N/A
Revenue Next Year
$120.94
N/A
P/E Ratio
$6.41
N/A
Revenue Growth
48.35
154.83
52 Week Low
$3.90
$0.24
52 Week High
$8.95
$5.12

Technical Indicators

Market Signals
Indicator
PROF
RLMD
Relative Strength Index (RSI) 55.25 61.68
Support Level $5.31 $3.49
Resistance Level $7.95 $5.05
Average True Range (ATR) 0.42 0.35
MACD 0.10 0.08
Stochastic Oscillator 75.38 89.73

Price Performance

Historical Comparison
PROF
RLMD

About PROF Profound Medical Corp.

Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.

About RLMD Relmada Therapeutics Inc.

Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

Share on Social Networks: